LYON, France--(BUSINESS WIRE)--Flamel Technologies (Nasdaq: FLML) is pleased that GlaxoSmithKline yesterday announced the U.S. nationwide availability of COREG CR™ (carvedilol phosphate) extended release tablets for use in treating three cardiovascular conditions:
